Figure 4. The evaluation of prediction capability of the tamoxifen efficacy-related long noncoding RNA (lncRNA) signature (TLS) in the validation dataset. (A) The expression profile of lncRNAs in TLS, the risk score of TLS and patients' distant metastasis-free survival (DMFS) were integrated and then evaluated in the validation cohort. (B) Patients classified by TLS with optimized cutoff value were evaluated in Kaplan-Meier analysis in the validation dataset.
HR=hazard ratio.